Outcomes of standard-of-care treatment for Hodgkin lymphoma are excellent¹.

The HD17 trial demonstrated patients treated with a PET-adapted approach, using two cycles of escBEACOPP followed by two cycles of ABVD (2+2), could forego consolidation radiation therapy without impacting progression-free survival, provided the end-of-treatment PET scan (PET4) demonstrated complete metabolic remission (with Deauville score 1 or 2)².  Omission of consolidation radiation likely results in lower rates of additional short- and long-term toxicity.

In the three years since publication of HD17 and the adoption of 2+2, there is yet to be published data assessing the real-world outcomes and treatment experience of these patients.

In this multicentre, retrospective, observational study, we hope to analyse standard efficacy outcomes and toxicity rates in this cohort.

1. Gillessen S, Plutschow A, Fuchs M, et al. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Lancet Haematol. 2021 Apr;8(4):e278-e288. doi: 10.1016/S2352-3026(21)00029-6.

2. Borchmann P, Plutschow A, Kobe C, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X.

Update 28/1/26 – Draft letter generated, awaiting review

Update 1/6/26 -Letter still in draft, but not yet submitted